Spots Global Cancer Trial Database for EPO906 Therapy in Patients With Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EPO906 Therapy in Patients With Prostate Cancer
Official Title: An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer
Study ID: NCT00035113
Conditions
Interventions
Study Description
Brief Summary: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Pacific Shores Medical Group, Long Beach, California, United States
California Pacific Medical Center, San Francisco, California, United States
University of Maryland - Greenbaum Cancer Center, Baltimore, Maryland, United States
Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
